Despite advances in acute stroke management, many survivors experience lasting motor and cognitive long-term sequelae. Acute reperfusion therapies and prevention strategies are well established, but options to enhance long-term motor and cognitive recovery remain limited. Several pharmacologic adjuncts (selective serotonin reuptake inhibitors (SSRIs), cholinesterase inhibitors, memantine) have shown inconsistent efficacy or safety, highlighting an unmet need for effective post-stroke recovery therapies. Growth hormone (GH) has emerged as a candidate adjunctive therapy based on its neurotrophic properties and the discovery of an endogenously activated neural GH axis following brain injury. This review aims to summarize GH's proposed mechanisms to promote neurorecovery after a stroke and to synthesize preclinical and clinical evidence supporting its use as an adjunct to standard post-stroke rehabilitation. A narrative review of preclinical and clinical studies that examined GH administration following ischemic stroke was conducted, emphasizing functional, cognitive, and safety outcomes; mechanistic findings connecting GH to neurotrophic signaling, synaptic plasticity, and cerebrovascular remodeling are also discussed. Preclinical studies demonstrated that GH administration after a stroke accelerates motor recovery, improves spatial and associative memory, reduces peri-infarct tissue loss, and increases neurotrophic, synaptic, and angiogenic markers (BDNF, IGF-1, VEGF). Four human clinical trials, along with the phase I-II COURAGE trial of GH-secretagogue therapy, reported significant improvements in functional independence (Korean Modified Barthel Index (K-MBI), motor and cognitive scores (Fugl-Meyer, Montreal Cognitive Assessment), and reduced neurological deficit (Modified Rankin Scale (mRS), National Institutes of Health Stroke Scale (NIHSS) in GH-treated patients compared with controls, without serious adverse events. Preclinical and early clinical evidence supports GH as a promising and safe adjunct to standard post-stroke rehabilitation, particularly for enhancing motor and cognitive recovery; however, existing clinical trials are small and varied in design, and larger, multicenter randomized controlled trials are required to establish optimal dosing, timing, and treatment duration before GH can be incorporated into standard post-stroke care.
Citation: Emmanuelle Zakheim, Daniel Moon, Wesley Tran, Ephrem Gerald, Mohamed Ahmed. Growth hormone as a treatment for post-stroke recovery: a review of preclinical and clinical evidence[J]. AIMS Neuroscience, 2026, 13(4): 651-666. doi: 10.3934/Neuroscience.2026030
Despite advances in acute stroke management, many survivors experience lasting motor and cognitive long-term sequelae. Acute reperfusion therapies and prevention strategies are well established, but options to enhance long-term motor and cognitive recovery remain limited. Several pharmacologic adjuncts (selective serotonin reuptake inhibitors (SSRIs), cholinesterase inhibitors, memantine) have shown inconsistent efficacy or safety, highlighting an unmet need for effective post-stroke recovery therapies. Growth hormone (GH) has emerged as a candidate adjunctive therapy based on its neurotrophic properties and the discovery of an endogenously activated neural GH axis following brain injury. This review aims to summarize GH's proposed mechanisms to promote neurorecovery after a stroke and to synthesize preclinical and clinical evidence supporting its use as an adjunct to standard post-stroke rehabilitation. A narrative review of preclinical and clinical studies that examined GH administration following ischemic stroke was conducted, emphasizing functional, cognitive, and safety outcomes; mechanistic findings connecting GH to neurotrophic signaling, synaptic plasticity, and cerebrovascular remodeling are also discussed. Preclinical studies demonstrated that GH administration after a stroke accelerates motor recovery, improves spatial and associative memory, reduces peri-infarct tissue loss, and increases neurotrophic, synaptic, and angiogenic markers (BDNF, IGF-1, VEGF). Four human clinical trials, along with the phase I-II COURAGE trial of GH-secretagogue therapy, reported significant improvements in functional independence (Korean Modified Barthel Index (K-MBI), motor and cognitive scores (Fugl-Meyer, Montreal Cognitive Assessment), and reduced neurological deficit (Modified Rankin Scale (mRS), National Institutes of Health Stroke Scale (NIHSS) in GH-treated patients compared with controls, without serious adverse events. Preclinical and early clinical evidence supports GH as a promising and safe adjunct to standard post-stroke rehabilitation, particularly for enhancing motor and cognitive recovery; however, existing clinical trials are small and varied in design, and larger, multicenter randomized controlled trials are required to establish optimal dosing, timing, and treatment duration before GH can be incorporated into standard post-stroke care.
Amplitude of Low-Frequency Fluctuations
Blood-Brain Barrier
Brain-Derived Neurotrophic Factor
Bis In Die (twice daily)
Blood-Oxygen-Level-Dependent
Bromodeoxyuridine
Blood Urea Nitrogen
Complete Blood Count
Cluster of Differentiation 31
Computed Tomography
Doublecortin
Dual-Energy X-ray Absorptiometry
Default Mode Network
Epidermal Growth Factor
Endothelin-1
Functional Ambulation Category
Functional Connectivity
Fugl-Meyer Assessment
Functional Magnetic Resonance Imaging
Growth Hormone
Growth Hormone, 3-month treatment group
Growth Hormone, 6-month treatment group
Growth Hormone Receptor
Growth Hormone-Releasing Peptide 6 (Growth Hormone-Releasing Hexapeptide)
Hemoglobin A1c
Intracerebroventricular
Insulin-like Growth Factor-1
Intravenous
Korean Modified Barthel Index
Korean Mini-Mental State Examination
Low-Density Lipoprotein (Cholesterol)
Myelin Basic Protein
Motricity Index
Manual Muscle Test/Strength
Montreal Cognitive Assessment
Modified Rankin Scale
Mechanistic (Mammalian) Target of Rapamycin
Neuronal Nuclei (neuronal marker)
National Institutes of Health Stroke Scale
Not Significant
Odds Ratio
p70 S6 Kinase
Paired-Associate Learning (task)
Postsynaptic Density Protein 95
Randomized Controlled Trial
Recombinant Human Growth Hormone
Repetitive Transcranial Magnetic Stimulation
Serious Adverse Event(s)
Subcutaneous
Subventricular Zone
Synapsin-1
Transcranial Direct Current Stimulation
Traumatic Brain Injury
Triglycerides
Veterans Affairs/Department of Defense
Vascular Endothelial Growth Factor
David Moon for help in designing and illustration of the original image, Figure 1.
The authors declare no conflict of interest.
Emmanuelle Zakheim: conceptualization, investigation, writing- original draft, writing-review and editing; Daniel Moon: investigation, writing-original draft, writing-review and editing; Wesley Tran: investigation, writing-review and editing; Ephrem Gerald: investigation, writing-reviewing and editing; Mohamed Ahmed: conceptualization, supervision, writing-reviewing and editing. All authors have read and agreed to the published version of the manuscript.
| [1] | GBD 2021 Stroke Risk Factor Collaborators.Global, regional, and national burden of stroke and its risk factors, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol (2024) 23: 973-1003. https://doi.org/10.1016/S1474-4422(24)00369-7 |
| [2] |
Ho JP, Powers WJ (2025) Contemporary management of acute ischemic stroke. Annu Rev Med 76: 417-429. https://doi.org/10.1146/annurev-med-050823-094312
|
| [3] | Mac Grory B, Xian Y, Solomon NC, et al. (2021) Exploring the unmet need in acute ischemic stroke patients not treated with intravenous alteplase: The get with the guidelines-stroke registry. Stroke Vasc Interv Neurol 2: e000226. https://doi.org/10.1161/SVIN.121.000226 |
| [4] |
Li X, Wu M, Zhang J, et al. (2025) Post-stroke dysphagia: Neurological regulation and recovery strategies. Biosci Trends 19: 31-52. https://doi.org/10.5582/bst.2025.01029
|
| [5] |
Huang J, Ji JR, Liang C, et al. (2022) Effects of physical therapy-based rehabilitation on recovery of upper limb motor function after stroke in adults: a systematic review and meta-analysis of randomized controlled trials. Ann Palliat Med 11: 521-531. https://doi.org/10.21037/apm-21-3710
|
| [6] |
Chen B, Yang T, Liao Z, et al. (2025) Pathophysiology and management strategies for post-stroke spasticity: An update review. Int J Mol Sci 26: 406. https://doi.org/10.3390/ijms26010406
|
| [7] |
Winstein CJ, Stein J, Arena R, et al. (2016) Guidelines for adult stroke rehabilitation and recovery: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 47: e98-e169. https://doi.org/10.1161/STR.0000000000000098
|
| [8] |
Eapen BC, Tran J, Ballard-Hernandez J, et al. (2025) Stroke Rehabilitation: Synopsis of the 2024 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guidelines. Ann Intern Med 178: 249-268. https://doi.org/10.7326/ANNALS-24-02205
|
| [9] |
Robinson RG, Jorge RE (2016) Post-stroke depression: a review. Am J Psychiatry 173: 221-231. https://doi.org/10.1176/appi.ajp.2015.15030363
|
| [10] |
El Husseini N, Katzan IL, Rost NS, et al. (2023) Cognitive impairment after ischemic and hemorrhagic stroke: a scientific statement from the American Heart Association/American Stroke Association. Stroke 54: e272-e291. https://doi.org/10.1161/STR.0000000000000430
|
| [11] |
Zhou Y, Feng H, Li G, et al. (2022) Efficacy of computerized cognitive training on improving cognitive functions of stroke patients: A systematic review and meta-analysis of randomized controlled trials. Int J Nurs Pract 28: e12966. https://doi.org/10.1111/ijn.12966
|
| [12] |
Amalia L (2026) Role of non-invasive brain stimulation with repetitive transcranial magnetic stimulation in improving fine motor performance of post-stroke patients: A systematic review and meta-analysis. BMC Neurol 26: 339. https://doi.org/10.1186/s12883-026-04839-z
|
| [13] |
Schlaug G, Renga V, Nair D (2008) Transcranial direct current stimulation in stroke recovery. Arch Neurol 65: 1571-1576. https://doi.org/10.1001/archneur.65.12.1571
|
| [14] | U.S. Department of Veterans AffairsVA/DoD clinical practice guideline for management of stroke rehabilitation* (Version 5.0) (2024). Available from: https://www.healthquality.va.gov/guidelines/rehab/stroke/index.asp |
| [15] |
Sanchez-Bezanilla S, Åberg ND, Crock P, et al. (2020) Growth hormone promotes motor function after experimental stroke and enhances recovery-promoting mechanisms within the peri-infarct area. Int J Mol Sci 21: 606. https://doi.org/10.3390/ijms21020606
|
| [16] |
Shin DH, Lee E, Kim JW, et al. (2004) Protective effect of growth hormone on neuronal apoptosis after hypoxia-ischemia in the neonatal rat brain. Neurosci Lett 354: 64-68. https://doi.org/10.1016/j.neulet.2003.09.070
|
| [17] |
Song J, Park K, Lee H, et al. (2012) The effect of recombinant human growth hormone therapy in patients with completed stroke: a pilot trial. Ann Rehabil Med 36: 447-457. https://doi.org/10.5535/arm.2012.36.4.447
|
| [18] | Legg LA, Rudberg AS, Hua X, et al. (2021) Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database of Systematic Reviews . https://doi.org/10.1002/14651858.CD009286.pub4 |
| [19] | Shenkin SD, Hewitt J, Quinn TJ (2021) Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis. Cochrane Database of Systematic Reviews . https://doi.org/10.1002/14651858.CD013306.pub2 |
| [20] |
Donato J, Kopchick JJ (2024) New findings on brain actions of growth hormone and potential clinical implications. Rev Endocr Metab Disord 25: 541-553. https://doi.org/10.1007/s11154-023-09861-x
|
| [21] |
Scheepens A, Sirimanne E, Beilharz E, et al. (1999) Alterations in the neural growth hormone axis following hypoxic-ischemic brain injury. Mol Brain Res 68: 88-100. https://doi.org/10.1016/S0169-328X(99)00051-0
|
| [22] |
Devesa P, Agasse F, Xapelli S, et al. (2014) Growth hormone pathways signaling for cell proliferation and survival in hippocampal neural precursors from postnatal mice. BMC Neurosci 15: 100. https://doi.org/10.1186/1471-2202-15-100
|
| [23] |
Falleti MG, Maruff P, Burman P, et al. (2006) The effects of growth hormone (GH) deficiency and GH replacement on cognitive performance in adults: a meta-analysis of the current literature. Psychoneuroendocrinology 31: 681-691. https://doi.org/10.1016/j.psyneuen.2006.01.005
|
| [24] |
Christophidis LJ, Gorba T, Gustavsson M, et al. (2009) Growth hormone receptor immunoreactivity is increased in the subventricular zone of juvenile rat brain after focal ischemia: A potential role for growth hormone in injury-induced neurogenesis. Growth Horm IGF Res 19: 497-506. https://doi.org/10.1016/j.ghir.2009.05.001
|
| [25] |
Scheepens A, Sirimanne ES, Breier BH, et al. (2001) Growth hormone as a neuronal rescue factor during recovery from CNS injury. Neuroscience 104: 677-687. https://doi.org/10.1016/S0306-4522(01)00109-9
|
| [26] |
Lillicrap T, Garcia-Esperon C, Walker FR, et al. (2018) Growth hormone deficiency is frequent after recent stroke. Front Neurol 9: 713. https://doi.org/10.3389/fneur.2018.00713
|
| [27] |
Popovic V (2005) GH deficiency as the most common pituitary defect after TBI: clinical implications. Pituitary 8: 239-243. https://doi.org/10.1007/s11102-006-6047-z
|
| [28] |
Ascoli P, Cavagnini F (2006) Hypopituitarism. Pituitary 9: 335-342. https://doi.org/10.1007/s11102-006-0416-5
|
| [29] |
Pathipati P, Surus A, Williams C E, et al. (2009) Delayed and chronic treatment with growth hormone after endothelin-induced stroke in the adult rat. Behav Brain Res 204: 93-101. https://doi.org/10.1016/j.bbr.2009.05.023
|
| [30] |
Ong LK, Chow WZ, TeBay C, et al. (2018) Growth hormone improves cognitive function after experimental stroke. Stroke 49: 1257-1266. https://doi.org/10.1161/STROKEAHA.117.020557
|
| [31] |
Sanchez-Bezanilla S, Beard DJ, Hood RJ, et al. (2022) Growth hormone increases BDNF and mTOR expression in specific brain regions after photothrombotic stroke in mice. Neural Plast 2022: 9983042. https://doi.org/10.1155/2022/9983042
|
| [32] |
Devesa P, Reimunde P, Gallego R, et al. (2011) Growth hormone (GH) treatment may cooperate with locally-produced GH in increasing the proliferative response of hippocampal progenitors to kainate-induced injury. Brain Inj 25: 503-510. https://doi.org/10.3109/02699052.2011.559611
|
| [33] |
Hong I, Lim Y, Han HS, et al. (2017) Application of the Korean Version of the Modified Barthel Index: Development of a keyform for use in Clinical Practice. Hong Kong J Occup Ther 29: 39-46. https://doi.org/10.1016/j.hkjot.2017.06.001
|
| [34] |
Han JS, Ryu SM, Lim YH, et al. (2024) Is the Korean mini-mental state examination (K-MMSE) useful in evaluating the cognitive function of brain injury patients?: Through correlation analysis with computerized neurocognitive test (CNT). Brain Neurorehabil 17: e13. https://doi.org/10.12786/bn.2024.17.e13
|
| [35] |
Jin GH, Lee JB (2018) Effect of recombinant human growth hormone add on therapy on acute stroke outcome. Brain Neurorehabil 11: e4. https://doi.org/10.12786/bn.2018.11.e4
|
| [36] |
Feng X, Li G, Wu W, et al. (2020) Recombinant human growth hormone ameliorates cognitive impairment in stroke patients. J Comput Assist Tomogr 44: 255-261. https://doi.org/10.1097/RCT.0000000000000990
|
| [37] |
Hernández-Bernal F, Estenoz-García D, Gutiérrez-Ronquillo JH, et al. (2024) Combination therapy of Epidermal Growth Factor and Growth Hormone-Releasing Hexapeptide in acute ischemic stroke: a phase I/II non-blinded, randomized clinical trial. Front Neurol 15: 1303402. https://doi.org/10.3389/fneur.2024.1303402
|